Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Alerts
  • Advertising/recruitment
  • Subscribe
  • Contact
  • Current Issue
  • Past Issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Author's Takes
  • Reviews
    • View all reviews ...
    • 100th Anniversary of Insulin's Discovery (Jan 2021)
    • Hypoxia-inducible factors in disease pathophysiology and therapeutics (Oct 2020)
    • Latency in Infectious Disease (Jul 2020)
    • Immunotherapy in Hematological Cancers (Apr 2020)
    • Big Data's Future in Medicine (Feb 2020)
    • Mechanisms Underlying the Metabolic Syndrome (Oct 2019)
    • Reparative Immunology (Jul 2019)
    • View all review series ...
  • Viewpoint
  • Collections
    • Recently published
    • In-Press Preview
    • Commentaries
    • Concise Communication
    • Editorials
    • Viewpoint
    • Top read articles
  • Clinical Medicine
  • JCI This Month
    • Current issue
    • Past issues

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Author's Takes
  • Recently published
  • In-Press Preview
  • Commentaries
  • Concise Communication
  • Editorials
  • Viewpoint
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Alerts
  • Advertising/recruitment
  • Subscribe
  • Contact
Top
  • View PDF
  • Download citation information
  • Send a letter
  • Share this article
  • Terms of use
  • Standard abbreviations
  • Need Help? E-mail the JCI
  • Top
  • Version history
  • Article usage
  • Citations to this article

Advertisement

Corrigendum Free access | 10.1172/JCI73378

An anticancer C-Kit kinase inhibitor is reengineered to make it more active and less cardiotoxic

Ariel Fernández, Angela Sanguino, Zhenghong Peng, Eylem Ozturk, Jianping Chen, Alejandro Crespo, Sarah Wulf, Aleksander Shavrin, Chaoping Qin, Jianpeng Ma, Jonathan Trent, Yvonne Lin, Hee-Dong Han, Lingegowda S. Mangala, James A. Bankson,10 Juri Gelovani, Allen Samarel,11 William Bornmann, Anil K. Sood,12 and Gabriel Lopez-Berestein

Find articles by Fernández, A. in: JCI | PubMed | Google Scholar

Find articles by Sanguino, A. in: JCI | PubMed | Google Scholar

Find articles by Peng, Z. in: JCI | PubMed | Google Scholar

Find articles by Ozturk, E. in: JCI | PubMed | Google Scholar

Find articles by Chen, J. in: JCI | PubMed | Google Scholar

Find articles by Crespo, A. in: JCI | PubMed | Google Scholar

Find articles by Wulf, S. in: JCI | PubMed | Google Scholar

Find articles by Shavrin, A. in: JCI | PubMed | Google Scholar

Find articles by Qin, C. in: JCI | PubMed | Google Scholar

Find articles by Ma, J. in: JCI | PubMed | Google Scholar

Find articles by Trent, J. in: JCI | PubMed | Google Scholar

Find articles by Lin, Y. in: JCI | PubMed | Google Scholar

Find articles by Han, H. in: JCI | PubMed | Google Scholar

Find articles by Mangala, L. in: JCI | PubMed | Google Scholar

Find articles by Bankson, J. in: JCI | PubMed | Google Scholar

Find articles by Gelovani, J. in: JCI | PubMed | Google Scholar

Find articles by Samarel, A. in: JCI | PubMed | Google Scholar

Find articles by Bornmann, W. in: JCI | PubMed | Google Scholar

Find articles by Sood, A. in: JCI | PubMed | Google Scholar

Find articles by Lopez-Berestein, G. in: JCI | PubMed | Google Scholar

Published November 1, 2013 - More info

Published in Volume 123, Issue 11 on November 1, 2013
J Clin Invest. 2013;123(11):4980–4980. https://doi.org/10.1172/JCI73378.
© 2013 The American Society for Clinical Investigation
Published November 1, 2013 - Version history
View PDF

Related article:

An anticancer C-Kit kinase inhibitor is reengineered to make it more active and less cardiotoxic
Ariel Fernández, … , Anil K. Sood, Gabriel Lopez-Berestein
Ariel Fernández, … , Anil K. Sood, Gabriel Lopez-Berestein
Technical Advance

An anticancer C-Kit kinase inhibitor is reengineered to make it more active and less cardiotoxic

  • Text
  • PDF
Abstract

Targeting kinases is central to drug-based cancer therapy but remains challenging because the drugs often lack specificity, which may cause toxic side effects. Modulating side effects is difficult because kinases are evolutionarily and hence structurally related. The lack of specificity of the anticancer drug imatinib enables it to be used to treat chronic myeloid leukemia, where its target is the Bcr-Abl kinase, as well as a proportion of gastrointestinal stromal tumors (GISTs), where its target is the C-Kit kinase. However, imatinib also has cardiotoxic effects traceable to its impact on the C-Abl kinase. Motivated by this finding, we made a modification to imatinib that hampers Bcr-Abl inhibition; refocuses the impact on the C-Kit kinase; and promotes inhibition of an additional target, JNK, a change that is required to reinforce prevention of cardiotoxicity. We established the molecular blueprint for target discrimination in vitro using spectrophotometric and colorimetric assays and through a phage-displayed kinase screening library. We demonstrated controlled inhibitory impact on C-Kit kinase in human cell lines and established the therapeutic impact of the engineered compound in a novel GIST mouse model, revealing a marked reduction of cardiotoxicity. These findings identify the reengineered imatinib as an agent to treat GISTs with curbed side effects and reveal a bottom-up approach to control drug specificity.

Authors

Ariel Fernández, Angela Sanguino, Zhenghong Peng, Eylem Ozturk, Jianping Chen, Alejandro Crespo, Sarah Wulf, Aleksander Shavrin, Chaoping Qin, Jianpeng Ma, Jonathan Trent, Yvonne Lin, Hee-Dong Han, Lingegowda S. Mangala, James A. Bankson, Juri Gelovani, Allen Samarel, William Bornmann, Anil K. Sood, Gabriel Lopez-Berestein

×

Original citation: J. Clin. Invest. 2007;117(12):4044–4054. doi:10.1172/JCI32373.

Citation for this corrigendum: J. Clin. Invest. 2013;123(11):4980. doi:10.1172/JCI73378.

During the preparation of this manuscript, information regarding an NIH grant was omitted from the Acknowledgments. The correct Acknowledgments section is below.

The research of A. Fernández was supported by NIH grant R01 GM072614 and by a grant from the Gulf Coast Center for Computational Cancer Research. J. Ma acknowledges support from the Welch Foundation. G. Lopez-Berestein acknowledges support from CA. A.K. Sood acknowledges support from the University of Texas MD Anderson Cancer Center SPORE in ovarian cancer (P50CA83639) and a Program Project Development Grant from the Ovarian Cancer Research Fund Inc. The GIST882 cells were a gift from Jonathan Fletcher, Dana-Farber Cancer Institute–Harvard Medical School. The experimental findings reported in Figure 5 validating the theoretical results in the paper were obtained in compliance with the aims and collaborative agreements with Eli Lilly and Co. specified in the NIH/NIGMS grant R01GM072614 (A. Fernandez, principal investigator).

The authors regret the error.

Version history
  • Version 1 (November 1, 2013): No description

Article tools

  • View PDF
  • Download citation information
  • Send a letter
  • Share this article
  • Terms of use
  • Standard abbreviations
  • Need Help? E-mail the JCI

Metrics

  • Article usage
  • Citations to this article

Go to

  • Top
  • Version history
Advertisement
Advertisement
Follow JCI:
Copyright © 2021 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts